
- Oncology NEWS International Vol 10 No 2
- Volume 10
- Issue 2
HER-2 Predicts Complete Pathologic Response to Chemo Neoadjuvant Chemotherapy
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
Optimal Care for HER2+ Breast Cancer
An interactive case challenge activity.
The goal of this activity is to clarify challenging treatment issues of HER2+ breast cancer including incorporation of predictive and prognostic biomarker tests and evidence-based data into practice when determining individualized strategies that improve patient survival and quality of life.
Go to Activity
Articles in this issue
over 24 years ago
Activated T Cells Can Alter Behavior of Leukemic B Cellsover 24 years ago
Response Continues for at Least 8 Months with Ibritumomab Tiuxetanover 24 years ago
Synthetic Anthracycline Produces High Response Rates in SCLCover 24 years ago
Ibritumomab Tiuxetan Produces 73% Response Rate in B-cell NHLover 24 years ago
G-CSF Might Prolong Rituximab Responses in NHLover 24 years ago
Use of CAD Increases the Early Detection of Breast Cancer by 20%Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.